Skip to main content

Trade-Ideas LLC identified

Intersect ENT



) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Intersect ENT as such a stock due to the following factors:

  • XENT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $11.7 million.
  • XENT has traded 65,832 shares today.
  • XENT is trading at 4.85 times the normal volume for the stock at this time of day.
  • XENT is trading at a new high 8.09% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in XENT with the Ticky from Trade-Ideas. See the FREE profile for XENT NOW at Trade-Ideas

More details on XENT:

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. XENT has a PE ratio of 8. Currently there are 7 analysts that rate Intersect ENT a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Intersect ENT has been 314,200 shares per day over the past 30 days. Intersect ENT has a market cap of $587.8 million and is part of the health care sector and health services industry. Shares are up 7.9% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.


TheStreet Quant Ratings

rates Intersect ENT as a


. Among the areas we feel are negative, one of the most important has been generally deteriorating net income.

Highlights from the ratings report include:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed against the S&P 500 and did not exceed that of the Pharmaceuticals industry. The net income has significantly decreased by 32.6% when compared to the same quarter one year ago, falling from -$4.38 million to -$5.81 million.
  • INTERSECT ENT INC has improved earnings per share by 8.0% in the most recent quarter compared to the same quarter a year ago. For the next year, the market is expecting a contraction of 18.0% in earnings (-$0.89 versus -$0.75).
  • Compared to other companies in the Pharmaceuticals industry and the overall market, INTERSECT ENT INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for INTERSECT ENT INC is currently very high, coming in at 81.96%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -38.24% is in-line with the industry average.
  • Net operating cash flow has fallen to -$2.29 million from having none in the same quarter last year. Since the company had no net operating cash flow for the prior period, we cannot calculate a percent change in order to compare its growth rate with that of its industry average.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.